
Captor
Therapeutics®
A NEW DAWN IN DRUG DISCOVERY
European Protein Degradation Congress 2021

Captor Therapeutics®

Important legal notice

This document and the information contained herein (unless otherwise indicated) have been prepared by Captor Therapeutics S.A. (the “Issuer”) solely for informational purposes. For this notice, the presentation that follows shall mean and include the slides that follow, the oral presentation of the slides by the Issuer or any person on behalf of the Issuer, any question-and-answer session that follows the oral presentation, hard copies of this document, and any materials distributed at, or in connection with the presentation (collectively, the “Presentation”). By attending the meeting at which the Presentation is made, or by reading the Presentation, you will be deemed to have (i) agreed to all of the following restrictions and made the following undertakings and (ii) acknowledged that you understand the legal and regulatory sanctions attached to the misuse, disclosure or improper circulation of the Presentation.

The information contained in this Presentation may not be reproduced or redistributed in any way, in whole or in part, to any other person without the prior written consent of the Issuer. This Presentation does not purport to contain all the information that may be required by the recipient to assess the Issuer or its securities. The Issuer prepared this Presentation based on the information which it has and from sources believed to be reliable. To the extent available, the industry, market, and competitive position data contained in this Presentation come from official or third-party sources. There is no guarantee of the accuracy or completeness of such data.

This Presentation contains neither a complete nor a comprehensive financial or commercial analysis of the Issuer, nor does it present its position or prospects in a complete or comprehensive manner. The Issuer has prepared the Presentation with due care, however certain inconsistencies or omissions might have appeared in it. Therefore it is recommended that any person who intends to undertake any investment decision regarding any security issued by the Issuer shall only rely on information released as an official communication (i.e. current/periodic reports) in accordance with the legal and regulatory provisions.

This Presentation may contain certain forward-looking statements, forecasts, estimates, projections, and opinions ("Forward-looking Statements"). By their nature, Forward-looking Statements involve known and unknown risks, uncertainties, assumptions, and other factors because they relate to events and depend on circumstances that will occur in the future whether or not outside the control of the Issuer. No representation is made or will be made that any Forward-looking Statements will be achieved or will prove to be correct. Actual future results and operations could vary materially from the Forward-looking Statements. Similarly, no representation is given that the assumptions disclosed in this Presentation upon which Forward-looking Statements may be based are reasonable. The recipient acknowledges that circumstances may change and the contents of this Presentation may become outdated as a result. The assumptions included herein do not constitute profit forecasts or profit estimates.

No warranties or representations can be made as to the comprehensiveness or reliability of the information contained in this Presentation. Neither the Issuer nor its directors, managers, advisers or representatives of such persons shall bear any liability that might arise in connection with any use of this Presentation. Furthermore, no information contained herein constitutes an obligation or representation of the Issuer, its managers or directors, its shareholders, subsidiary undertakings, advisers or representatives of such persons.

Data contained in this Presentation is valid as of the day of its preparation. Consequently, this Presentation will not be subject to changes, updates or modifications to account for events which might occur after this day.

This Presentation does not constitute or form part of, and should not be construed as, an offer to sell or issue, or the solicitation of an offer to purchase, subscribe to, or acquire the Issuer or the Issuer´s securities, or an inducement to enter into investment activity in any jurisdiction in which such offer, solicitation, inducement or sale would be unlawful before registration, exemption from registration or qualification under the securities laws of such jurisdiction. No part of this Presentation, nor the fact of its distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. This presentation is not for publication, release, or distribution in any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction nor should it be taken or transmitted into such jurisdiction.

Captor Therapeutics S. A. – next generation targeted protein degradation



- Based in Wroclaw (Poland) and Basel (Switzerland)
- Broad TPD platform established in 2017
- Five drug programs in large potential markets
- ~85 FTEs on board, 44% PhD level specialists
- 1,100 m^2 state-of-the-art laboratory
- Discovery collaboration with Sosei Heptares
- 2021 IPO on the Warsaw Stock Exchange

A global, highly qualified team:

An experienced leadership team

Tom Shepherd, Ph.D.

Chief Executive Officer

- 30 years in Business Development and CEO posts in USA & Europe
- Led 12 licensing transactions
- 6 private investment rounds and participated in 3 IPOs.

EDUCATION

University of Strathclyde Glasgow · London Business School

PREVIOUS EXPERIENCE

BAUSCH Health · kymab

Sylvain Cottens, Ph.D.

SVP Chemistry

- 30 years experience former Global Head, Center for Proteomic Chemistry at Novartis
- Co-inventor of Afinitor
- Key role in Gilenya license to Novartis

EDUCATION

EPFL

PREVIOUS EXPERIENCE

NOVARTIS

Michal Walczak, Ph.D.

Chief Scientific Officer

- Ph.D. ETH Zurich,
- Post-doc FMI Basel (Novartis Research Foundation) on targeted protein degradation
- 10 years experience in drug discovery and protein degradation

EDUCATION

Uniwersytet Wrocławski · ETH

PREVIOUS EXPERIENCE

FMI Friedrich Miescher Institute for Biomedical Research

Radoslaw Krawczyk

Chief Financial Officer

- Finance & banking Warsaw School of Economics
- MBA Marseille Graduate School of Management
- 20 years in Financial Strategy
- 8 years in listed companies on WSE
- 2 IPOs

EDUCATION

Szkoła Główna Handlowa Warsaw School of Economics · gfkm · IAE AIX Aix-Marseille Graduate School of Management

PREVIOUS EXPERIENCE

PKPCARGO · OT LOGISTICS

A balanced pipeline

Captor

Novel therapies against drug targets that have not been previously addressed with classical drugs



Partnership development

Gastrointestinal diseases, i.a. IBD

Partnered with SOSEI HEPTARES

Balanced pipeline with both undrugged and validated targets

Three pillars of Captor's Optigrade™ platform

Current

Next Generation

I Molecular Glues



Molecular glue

II Bifunctional Degraders



Bifunctional Degrader

III LiLis™



Captor exploits all these components to maximise the probability of developing a successful drug

The clinically established modalities for TPD

Captor

Molecular Glues



Revlimid and Pomalyst, Celgene successful molecular glue drugs

Very good biopharmaceutical properties

Bifunctional Degrader



Arvinas' degraders, ARV-471 & ARV-110, show efficacy in Phase 1/2 in patients[1]

[1]https://ir.arvinas.com/news-releases/news-release-details/arvinas-releases-interim-clinical-data-further-demonstrating

A modular design potentially applicable to any target protein

Captor's improved approach with enhanced selectivity

Captor's Molecular Glues



- Unique and proprietary library
- Guided approach to the screening against putative neosubstrates
- Pipeline glues have enhanced selectivity
- Demonstrated efficacy and oral bioavailability

Captor's Bifunctional Degraders



- Proprietary ligase ligands without intrinsic glue activity
- Novel, improved bifunctional degraders with enhanced stability
- Pharmacodynamic effect demonstrated

Leveraging Optigrade™ platform in Hepatocellular Carcinoma

- Accounts for 75-85% of primary liver cancers[1]
- Liver cancer
  - 5th most common cancer in men[1]
  - 9th most common cancer in women[1]
- Curative treatments are restricted to early disease
- High rate of metastases
- 5-year Survival Rates[2] vary from 3% to 34% depending on disease stage at the diagnosis



[1] *Global Cancer Statistics 2018,* [2] *Data for the US, 2010-2016, ACS Cancer Facts & Figures*

CT-01 - Molecular glue programme in HCC

- Derived from the Captor library of CRBN-based molecular glues
- Captor's glues have unique degradation profiles and physicochemical properties
- Potent molecular glues selectively active against a panel of HCC cell lines





Comparison between the antiproliferative activity of Captor's glue and lenalidomide in HCC using BrdU assay (left) and clonogenic assay (right)

CT-01 compounds potent activity across HCC cell lines

Captor

Expanding the panel of sensitive HCC models



Increased degradation potency correlates with higher cellular activity



Potent target degradation in an HCC cell line



Selectivity over targets degraded by known CRBN-based glues, such as CC-220, in PBMCs

Progress of the HCC programme



- ✓ A series of glues with unique degradation profiles
- ✓ Good oral bioavailability achieved
- ✓ *In vivo* studies ongoing

CT-03 - targeting apoptosis with bifunctional degraders

- ✓ CT-03 target - a major factor of resistance in solid and liquid tumours
- ✓ Signalling via protein-protein interactions
- ✓ Undrugged target despite significant efforts



Potent degraders of POI induce apoptosis



Ternary complex formation with POI and the ligase, AlphaLISA



PoI degradation in MM cells

- ✓ Developed a series of bifunctional degraders against the target
- ✓ Robust cytotoxic activity in numerous blood cancers confirmed
- ✓ Currently generating *in vivo* data to select a clinical candidate



POI degrader causes a concentration dependent increase in early apoptotic cells (Annexin +/PI -) and late apoptotic/cell death (Annexin +/PI +)

In vivo activity of CT-03 bifunctional degraders

- ✓ Selected representatives of the lead series induce almost complete degradation of POI *in vivo*
- ✓ POI degradation *in vivo* is followed by apoptosis induction
- ✓ Efficacy study in AML model in preparation









LiLis™: E3 ligase ligands for next generation degraders

- ✓ Multidimensional analysis of ligases' biological profile
- ✓ A large library of E3 ligases produced
- ✓ Ligase ligand generation for novel E3s with differentiated profiles
- ✓ Ligands identified and crystal structures solved
- ✓ Prototyping bifunctional degraders for novel E3s



A snapshot of Captor's Ligase Knowledge Database



Novel TPD ligases to be selected based on the biological context of the disease

Company Highlights

- The first TPD-dedicated public company in Europe
- Innovative modular drug discovery platform with existing validating partnership
- Five fully-owned, differentiated drug projects addressing high value markets with significant unmet medical need
- Comprehensive TPD platform with focus on good druggable properties


Captor
Therapeutics®
THANK YOU

Projects are co-financed by the European Regional Development Fund:

Discovery and development of a new clinical drug candidate for the eradication of cancer stem cell in the treatment of hepatocellular carcinoma, through degradation of oncofetal transcription factor
(POIR.01.01.01-00-0740/19)

Inducing apoptosis with small molecules as therapeutic intervention in multiple severe malignancies
(POIR.01.01.01-00-0956/17-01)

Discovery and development of first-in-class of small molecule degrader as a drug candidate for the treatment of colorectal cancer
(POIR.01.02.00-00-0073/18-00)

Development of an integrated technology platform in the field of targeted protein degradation and its implementation to the pharmaceutical market
(POIR.01.01.01-00-0931/19-00)

Elaboration of interaction assays suitable for screening of the chemical compounds used in a first-in-class drug development
(POIR.04.01.02-00-0147/16)

European Funds Smart Growth | Republic of Poland | The National Centre for Research and Development | European Union European Regional Development Fund